Provided by Tiger Trade Technology Pte. Ltd.

Rani Therapeutics Holdings

0.8400
-0.0142-1.66%
Pre-market: 0.87800.0380+4.52%07:30 EDT
Volume:371.37K
Turnover:314.90K
Market Cap:117.09M
PE:-3.86
High:0.8610
Open:0.8600
Low:0.8360
Close:0.8542
52wk High:3.87
52wk Low:0.4404
Shares:139.40M
Float Shares:85.67M
Volume Ratio:0.66
T/O Rate:0.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2174
EPS(LYR):-0.4500
ROE:-172.15%
ROA:-52.99%
PB:2.98
PE(LYR):-1.87

Loading ...

Rani Therapeutics Holdings Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice

TIPRANKS
·
May 16

Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition

Reuters
·
May 16

Rani Therapeutics Holdings Inc - Svai Sanford to Remain CFO During Transition Period

THOMSON REUTERS
·
May 16

Rani Therapeutics Q1 Operating Income USD -8.339 Million

THOMSON REUTERS
·
May 16

Press Release: Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

Dow Jones
·
May 16

Rani Therapeutics Holdings Inc expected to post a loss of 4 cents a share - Earnings Preview

Reuters
·
May 09

Rani Therapeutics Holdings announces annual shareholder meeting via webcast

Reuters
·
Apr 17

Rani Therapeutics names Sara Kenkare-Mitra strategic advisor on platform, clinical strategy

Reuters
·
Apr 09

Analysts Conflicted on These Healthcare Names: Rani Therapeutics Holdings (RANI) and Apellis Pharmaceuticals (APLS)

TIPRANKS
·
Apr 01

Rani Therapeutics files initial beneficial ownership statement; Chief Technical Officer Alireza Javadi reports 10,075 Class A shares

Reuters
·
Mar 28

Rani Therapeutics Holdings Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Mar 27

Rani Therapeutics' net loss narrows in Q4 as costs fall

Reuters
·
Mar 27

Rani Therapeutics FY2025 net loss narrows 27.6% to $41 million; revenue rises 58.9% to $1.6 million

Reuters
·
Mar 27

Rani Therapeutics Q4 Operating Expenses USD 9.995 Million

THOMSON REUTERS
·
Mar 27

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

GlobeNewswire
·
Mar 27

Rani Therapeutics Holdings options imply 17.3% move in share price post-earnings

TIPRANKS
·
Mar 27

Press Release: Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Dow Jones
·
Mar 26

Rani Therapeutics Holdings Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
Mar 25

Rani Therapeutics Holdings Inc expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
Mar 21